UK markets open in 4 hours 18 minutes

Tiziana Life Sciences PLC (TIZAF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
1.30000.0000 (0.00%)
At close: 9:30AM EDT

Tiziana Life Sciences PLC

55 Park Lane
London W1K 1NA
United Kingdom
44 20 7495 2379
http://www.tizianalifesciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees11

Key executives

NameTitlePayExercisedYear born
Mr. Gabriele Marco Antonio Cerrone M.B.A., MBAFounder & Exec. Chairman13.76MN/A1972
Dr. Kunwar ShailubhaiCEO, Chief Scientific Officer & Exec. Director810kN/A1958
Dr. Andrea BrancaleScientific FounderN/AN/AN/A
Mr. Richard Clarkson Ph.D.Scientific FounderN/AN/AN/A
Mr. Andrew Westwell Ph.D.Scientific FounderN/AN/AN/A
Ms. Keeren ShahFin. DirectorN/AN/A1977
Dr. Thomas H. AdamsHead of Drug Devel. & Exec. DirectorN/AN/A1943
Dr. Neil Graham M.P.H., MBBS, M.D., MPHChief Medical OfficerN/AN/A1959
Dr. Napoleone FerraraChairman of Scientific Advisory BoardN/AN/A1958
Prof. Roberto PellicciariConsultantN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.

Corporate governance

Tiziana Life Sciences PLC’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.